InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,716.19
(
0.24%
)
US TECH 100
19,316.85
(
0.10%
)
Dow Jones
42,134.31
(
0.17%
)
Brent Oil
73.27
(
-0.84%
)
Bitcoin
63,375.83
(
-0.39%
)
Post# of 438
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DanWebzster

Send PM Follow Ignore
Followers 10
Posts 1060
Boards Moderated 2
Alias Born 09/04/2000

DanWebzster

Member Level

Re: DanWebzster post# 310

Tuesday, 08/21/2018 10:39:12 AM

Tuesday, August 21, 2018 10:39:12 AM

Post# of 438
CNST is a 6/18 Oncology IPO that focuses on epigenetic regulators

Lead program is a Ph2 combo trial in Metastatic Castrate-Resistant Prostate Cancer. Proof of Concept results should be available mid/19.

Proof of concept results will also be available mid/19 for their Ph2 combo trial in Myelofibrosis

Cash runway is into H2/2020.

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up